Suppr超能文献

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

作者信息

Barrett Jordan R, Belij-Rammerstorfer Sandra, Dold Christina, Ewer Katie J, Folegatti Pedro M, Gilbride Ciaran, Halkerston Rachel, Hill Jennifer, Jenkin Daniel, Stockdale Lisa, Verheul Marije K, Aley Parvinder K, Angus Brian, Bellamy Duncan, Berrie Eleanor, Bibi Sagida, Bittaye Mustapha, Carroll Miles W, Cavell Breeze, Clutterbuck Elizabeth A, Edwards Nick, Flaxman Amy, Fuskova Michelle, Gorringe Andrew, Hallis Bassam, Kerridge Simon, Lawrie Alison M, Linder Aline, Liu Xinxue, Madhavan Meera, Makinson Rebecca, Mellors Jack, Minassian Angela, Moore Maria, Mujadidi Yama, Plested Emma, Poulton Ian, Ramasamy Maheshi N, Robinson Hannah, Rollier Christine S, Song Rinn, Snape Matthew D, Tarrant Richard, Taylor Stephen, Thomas Kelly M, Voysey Merryn, Watson Marion E E, Wright Daniel, Douglas Alexander D, Green Catherine M, Hill Adrian V S, Lambe Teresa, Gilbert Sarah, Pollard Andrew J

机构信息

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

出版信息

Nat Med. 2021 Jun;27(6):1113. doi: 10.1038/s41591-021-01372-z.

DOI:10.1038/s41591-021-01372-z
PMID:33958800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8101331/
Abstract
摘要

相似文献

1
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med. 2021 Jun;27(6):1113. doi: 10.1038/s41591-021-01372-z.
2
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
3
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17.
4
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
5
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV. 2021 Sep;8(9):e568-e580. doi: 10.1016/S2352-3018(21)00157-0. Epub 2021 Aug 17.
6
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine. 2022 Nov;85:104298. doi: 10.1016/j.ebiom.2022.104298. Epub 2022 Oct 10.
7
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
8
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
J Infect. 2025 Feb;90(2):106423. doi: 10.1016/j.jinf.2025.106423. Epub 2025 Jan 16.
9
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Sci Rep. 2024 Apr 29;14(1):9830. doi: 10.1038/s41598-024-57308-3.
10
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
EBioMedicine. 2021 Aug;70:103523. doi: 10.1016/j.ebiom.2021.103523. Epub 2021 Aug 12.

引用本文的文献

1
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections.
Vaccines (Basel). 2024 Apr 29;12(5):478. doi: 10.3390/vaccines12050478.
2
Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients.
Ren Fail. 2023 Dec;45(1):2172432. doi: 10.1080/0886022X.2023.2172432.
3
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Front Immunol. 2023 Jan 13;13:1062067. doi: 10.3389/fimmu.2022.1062067. eCollection 2022.
4
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine.
Cell Rep Med. 2022 Jul 19;3(7):100685. doi: 10.1016/j.xcrm.2022.100685.
5
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Front Immunol. 2022 Jun 21;13:917905. doi: 10.3389/fimmu.2022.917905. eCollection 2022.
6
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Allergy. 2022 Aug;77(8):2431-2445. doi: 10.1111/all.15305. Epub 2022 Apr 15.
7
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.
Hum Vaccin Immunother. 2021 Dec 2;17(12):5532-5545. doi: 10.1080/21645515.2021.1985891. Epub 2021 Nov 29.
8
The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.
Immunother Adv. 2021 Aug 17;1(1):ltab019. doi: 10.1093/immadv/ltab019. eCollection 2021 Jan.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验